Impact of donor-specific antibodies on results of liver transplantation

Current Opinion in Organ Transplantation

Volumn 18, Issue 3, 2013, Pages 279-284

  O'Leary, Jacqueline G ^a   Klintmalm, Goran B ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Donor specific antibodies; Liver transplantation; Outcomes; Simultaneous liver kidney transplant

Indexed keywords

ANTIBODY; DONOR SPECIFIC ANTIBODY; HLA ANTIGEN; UNCLASSIFIED DRUG; AUTOANTIBODY; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; PEPTIDE FRAGMENT;

ACUTE GRAFT REJECTION; ALLOGRAFT; AUTOIMMUNE HEPATITIS; CHRONIC GRAFT REJECTION; DE NOVO AUTOIMMUNE HEPATITIS; DONOR; FLUORESCENCE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; LIVER FIBROSIS; LIVER GRAFT; LIVER TRANSPLANTATION; REVIEW; SIMULTANEOUS LIVER KIDNEY TRANSPLANTATION; TREATMENT OUTCOME; IMMUNOLOGY;

AUTOANTIBODIES; COMPLEMENT C4B; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PEPTIDE FRAGMENTS; TISSUE DONORS;

MLCS; MLOWN;

EID: 84879963756     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283614a10     Document Type: Review

References (24)

1. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11:1868-1876.
2. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11:500-510.
3. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18:1333-1342.
4. Iacob S, Cicinnati VR, Dechene A, et al. Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation. Liver Int 2012; 32:1253-1261.
5. Aguilera I, Sousa JM, Gavilan F, et al. Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis. Liver Transpl 2011; 17:779-788.
6. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donorspecific antibodies. Liver Transpl 2011; 17:357-368.
7. Paterno F, Shiller SM, Tillery GW, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12:2526-2531.
8. Dar W, Agarwal A, Watkins C, et al. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11:841-847.
9. O'Leary JG, Gebel HM, Ruiz R, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013 (in press).
10. Gordon RD, Fung JJ, Markus B, et al. The antibody crossmatch in liver transplantation. Surgery 1986; 100:705-715.
11. Takaya S, Duquesnoy R, Iwaki Y, et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23:396-399.
12. Ogura K, Koyama H, Takemoto S, et al. Significance of a positive crossmatch on outcome in human liver transplantation. Transplant Proc 1992; 24:1465.
13. Ratner LE, Phelan D, Brunt EM, et al. Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient. Transplantation 1993; 55:814-819.
14. Demetris AJ, Markus BH, Burnham J, et al. Antibody deposition in liver allografts with chronic rejection. Transplant Proc 1987; 19 (4 Suppl 5): 121-125.
15. Takaya S, Jain A, Yagihashi A, et al. Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc 1999; 31:2028-2031.
16. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14:554-562.
17. Goh A, Scalamogna M, De Feo T, et al. Human leukocyte antigen crossmatch testing isimportant for liver retransplantation. Liver Transpl 2010; 16:308-313.
18. Kaneku H, O'Leary JG, Taniguchi M, et al. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18:984-992.
19. Starzl TE, Demetris AJ, Todo S, et al. Evidence for hyperacute rejection of human liver grafts: the case of the canary kidneys. Clin Transplant 1989; 3:37-45.
20. Olausson M, Mjornstedt L, Norden G, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007; 7:130-136.
21. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. J Am Med Assoc 2012; 307:283-293.
22. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12:1504-1510.
23. Mengel M, Sis B, Haas M, et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12:563-570.
24. Lunz J, Ruppert KM, Cajaiba MM, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2012; 12:171-182.